About Canopy Growth Corporation - Common Shares (CGC)
Canopy Growth Corp is a leading player in the cannabis industry, focusing on the production and distribution of a wide range of cannabis products. The company is engaged in cultivating and processing cannabis for both medical and recreational purposes, offering various forms such as dried flower, oils, edibles, and beverages. With a commitment to innovation, Canopy Growth invests in research and development to create high-quality products that meet consumer demands and adhere to evolving regulations. The company also emphasizes sustainability and responsible business practices, aiming to shape the future of cannabis consumption and enhance the overall experience for consumers. Read More
Cannabis remains listed as a Schedule I substance under the Controlled Substances Act (CSA), a category reserved for drugs considered to have a high likelihood of misuse and no recognized medical purpose. That designation has shaped federal drug policy for decades and continues to influence workplace rules across the country.
Cannabis remains listed as a Schedule I substance under the Controlled Substances Act (CSA), a category reserved for drugs considered to have a high likelihood of misuse and no recognized medical purpose. That designation has shaped federal drug policy for decades and continues to influence workplace rules across the country.
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) is pleased to announce that shareholders of MTL Cannabis Corp. (“MTL Cannabis” or “MTL”) have voted to approve the Company’s previously announced acquisition of MTL (the “Transaction”) at a special meeting of shareholders of MTL (the “MTL Shareholders”) held February 17, 2026.
Constellation Brands (NYSE: STZ), the titan of Mexican beer imports and premium spirits, finds itself at a critical crossroads. After a decade defined by the explosive ascent of Modelo Especial—which famously dethroned Bud Light as America’s top-selling beer—the company is now grappling with a sobering reality. On February 12, 2026, Constellation announced a major leadership [...]
Expanding legal access to marijuana for both recreational and medical use may be linked to lower levels of daily opioid consumption among people who inject substances, according to new research led by a scholar at the Boston University School of Public Health.
Expanding legal access to marijuana for both recreational and medical use may be linked to lower levels of daily opioid consumption among people who inject substances, according to new research led by a scholar at the Boston University School of Public Health.
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announced its financial results for the three months ended December 31, 2025 ("Q3 FY2026"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026.
A new scientific review is challenging the foundations of U.S. drug law, arguing that the legal system governing controlled substances no longer reflects modern scientific understanding of risk.
A new scientific review is challenging the foundations of U.S. drug law, arguing that the legal system governing controlled substances no longer reflects modern scientific understanding of risk.
As of January 9, 2026, the cannabis sector finds itself at a historic crossroads, caught between the euphoria of federal progress and the harsh reality of market mechanics. Following a landmark Executive Order in late 2025 aimed at accelerating the rescheduling of marijuana, the industry has entered the new year
